Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

McGill University

$92,313.00

Rapidly-Gelling, Guanosine 5' Diphosphate-Crosslinked Injectable Chitosan Sponges to Promote Oligodendrocyte Progenitor Cells' Differentiation Post-Spinal Cord Injuries

EF 2015-16

Résumé
In Canada, there are approximately 86,000 Canadians living with spinal cord injuries (SCI). The economic burden caused by SCI is immense, costing Canada an estimated $3.6 billion/Y. The initial trauma causes a contusion injury to the spinal cord resulting in damage to neurons and oligodendrocytes (OLGs). Secondary to trauma, there is additional neuronal and axonal loss, and damage to myelin and glia. The loss of myelin surrounding intact axons (demyelination) can result in functional loss because of the inability of these axons to effectively conduct nerve impulses. At present there are no effective treatments for SCI, and although many researchers are interested in neural regeneration, none are focused on developing biomaterials to target remyelination post-SCI. Therefore, the overall objective of this proposal is to use an injectable scaffold containing neurotrophic factors to promote the differentiation of endogenous OPCs and improve remyelination and neurological function post-SCI. We successfully developed a novel, rapidly-gelling, injectable chitosan sponge using Guanosine 5-diphosphate (GDP). The sponges gel in less than 2 seconds, a highly desirable property to ensure localization at the site of injection. Moreover, the sponges were found to have very desirable physicochemical properties and excellent cytocompatibility. Brain Derived Neurotrophic Factor (BDNF) was successfully entrapped and released from the sponges in a controlled manner for up to 3 weeks. Furthermore, we demonstrated the successful attachment and differentiation of rat OPCs' on the chitosan sponges. Further studies are still required using rat OPCs to investigate myelination on the sponges. Furthermore, fetal and adult human OPCs survival and differentiation on the sponges will be assessed. Finally, chitosan sponges will be injected in a contused mouse spinal cord model to study remyelination and recovery of neurological functions.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
462506-2014
Name nom
Tabrizian, Maryam
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2014
Award amount
92313
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Rapidly-Gelling, Guanosine 5' Diphosphate-Crosslinked Injectable Chitosan Sponges to Promote Oligodendrocyte Progenitor Cells' Differentiation Post-Spinal Cord Injuries
Keyword
NSERC
Application summary
In Canada, there are approximately 86,000 Canadians living with spinal cord injuries (SCI). The economic burden caused by SCI is immense, costing Canada an estimated $3.6 billion/Y. The initial trauma causes a contusion injury to the spinal cord resulting in damage to neurons and oligodendrocytes (OLGs). Secondary to trauma, there is additional neuronal and axonal loss, and damage to myelin and glia. The loss of myelin surrounding intact axons (demyelination) can result in functional loss because of the inability of these axons to effectively conduct nerve impulses. At present there are no effective treatments for SCI, and although many researchers are interested in neural regeneration, none are focused on developing biomaterials to target remyelination post-SCI. Therefore, the overall objective of this proposal is to use an injectable scaffold containing neurotrophic factors to promote the differentiation of endogenous OPCs and improve remyelination and neurological function post-SCI. We successfully developed a novel, rapidly-gelling, injectable chitosan sponge using Guanosine 5-diphosphate (GDP). The sponges gel in less than 2 seconds, a highly desirable property to ensure localization at the site of injection. Moreover, the sponges were found to have very desirable physicochemical properties and excellent cytocompatibility. Brain Derived Neurotrophic Factor (BDNF) was successfully entrapped and released from the sponges in a controlled manner for up to 3 weeks. Furthermore, we demonstrated the successful attachment and differentiation of rat OPCs' on the chitosan sponges. Further studies are still required using rat OPCs to investigate myelination on the sponges. Furthermore, fetal and adult human OPCs survival and differentiation on the sponges will be assessed. Finally, chitosan sponges will be injected in a contused mouse spinal cord model to study remyelination and recovery of neurological functions.